ARS Pharmaceuticals, Inc. (SPRY): who owns it and who trades it
As of Nov 16, 2026, SPRY insiders reported 2 open-market sales worth $284K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Eric Karas (Chief Commercial Officer), with $250K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling ARS Pharmaceuticals
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SPRY
205 funds and institutions reported SPRY shares worth $731M at the end of Q2 2026, about 92% of the company. The largest holder is Ra Capital Management, L.P. with 10.9%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10.86M | 10.94% | $87M | No change |
| Rubric Capital Management LP | 8.54M | 8.60% | $68.4M | +7% |
| Orbimed Advisors LLC | 8.29M | 8.35% | $66.4M | No change |
| Deerfield Management Company, L.P. | 7.50M | 7.56% | $60.1M | No change |
| BlackRock, Inc. | 5.31M | 5.35% | $42.5M | +6% |
| Tyro Capital Management LLC | 4.46M | 4.49% | $35.7M | +50% |
| Aberdeen Group plc | 4.17M | 4.20% | $33.4M | +1% |
| SR One Capital Management, LP | 4.01M | 4.04% | $32.1M | No change |
| State Street Corp | 3.73M | 3.76% | $29.9M | +2% |
| Capital World Investors | 2.75M | 2.77% | $22.1M | – |
| Vanguard Capital Management LLC | 2.55M | 2.57% | $20.5M | +0% |
| Millennium Management LLC | 2.40M | 2.42% | $19.2M | -60% |
| Janney Montgomery Scott LLC | 2.06M | 2.08% | $16.5M | +2% |
| UBS Group AG | 1.94M | 1.95% | $15.5M | -14% |
| Geode Capital Management, LLC | 1.70M | 1.71% | $13.6M | +11% |
| Boothbay Fund Management, LLC | 1.60M | 1.61% | $12.8M | +539% |
| General American Investors Co Inc | 1.13M | 1.14% | $9.1M | +56% |
| Third Point LLC | 1.00M | 1.01% | $8M | No change |
| Peregrine Capital Management LLC | 672,139 | 0.68% | $5.4M | – |
| Tejara Capital Ltd | 607,039 | 0.61% | $4.9M | +189% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SPRY insiders reported $0 of open-market purchases and $284K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Eric Karas | Chief Commercial Officer | Sale plan | 25,000 | $10.00 | $250K | Form 4 |
| Jun 12, 2026 | Alexander A Fitzpatrick | Chief Legal Officer | Sale plan | 3,355 | $10.00 | $33.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Eric Karas | Chief Commercial Officer | – | $250K | Jun 12, 2026 |
| Alexander A Fitzpatrick | Chief Legal Officer | – | $33.5K | Jun 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SPRY short interest
High short interest. 19.1% of SPRY shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 27%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 18.99M SPRY shares were sold short, 19.1% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 11.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 18.99M | 19.10% | -4% | 1.71M | 11.1 |
| Oct 15, 2026 | 19.82M | 19.93% | -6% | 1.58M | 12.6 |
| Sep 30, 2026 | 21.19M | 21.31% | -8% | 1.32M | 16.1 |
| Sep 15, 2026 | 23.07M | 23.20% | -1% | 1.49M | 15.5 |
| Aug 31, 2026 | 23.21M | 23.34% | +1% | 1.64M | 14.1 |
| Aug 14, 2026 | 22.95M | 23.08% | +7% | 2.08M | 11.0 |
| Jul 31, 2026 | 21.45M | 21.60% | -5% | 2.76M | 7.8 |
| Jul 15, 2026 | 22.67M | 22.83% | +4% | 1.48M | 15.3 |
| Jun 30, 2026 | 21.73M | 21.89% | -6% | 2.54M | 8.6 |
| Jun 15, 2026 | 23.09M | 23.25% | -9% | 1.31M | 17.6 |
| May 29, 2026 | 25.50M | 25.68% | -2% | 1.81M | 14.1 |
| May 15, 2026 | 25.91M | 26.10% | -1% | 1.95M | 13.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
ARS Pharmaceuticals company events
ARS Pharmaceuticals filed 8 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 17, 2026LeadershipRichard Lowenthal resigned as a member of the Board of Directors of ARS Pharmaceuticals, Inc., effective immediately. Filing
- Jul 7, 2026LeadershipThe Board of Directors of ARS Pharmaceuticals, Inc. appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity. Filing
- Jun 25, 2026VoteReported shareholder vote results. Filing
- May 15, 2026ResultsReleased financial results. Filing
- May 13, 2026LeadershipThe Board of Directors of ARS Pharmaceuticals, Inc., a Delaware corporation, based in part on the recommendation of Richard Lowenthal, the Company’s Chief Executive Officer, appointed Donn Casale as the Company’s President effective as of the date he commences employment with the Company, which… Filing
- Mar 9, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
ARS Pharmaceuticals financials
Famous investors that hold SPRY
5 of the 50 well-known investors we track reported holding SPRY in their latest 13F filing. The largest position is Israel Englander's, worth $14.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 3.27M | $14.1M | 0.0% | +36% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.08M | $4.6M | 0.0% | +103% |
| Dan Loeb · Third Point | Q3 2026 | 1.00M | $4.3M | 0.1% | No change |
| Jim Simons · Renaissance Technologies | Q3 2026 | 174,200 | $751K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 45,895 | $198K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about ARS Pharmaceuticals, Inc. (SPRY) stock
Who owns the most SPRY stock?
The largest reported owner of ARS Pharmaceuticals, Inc. (SPRY) is Ra Capital Management, L.P., with 10.9% of the company. In total, 205 funds and institutions reported holding SPRY at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are SPRY insiders buying or selling?
In the last 12 months, SPRY insiders reported no open-market purchases and 2 sales worth $284K. The latest trade was on Jun 12, 2026. See every trade.
What is the short interest in SPRY?
As of Oct 30, 2026, 18.99M SPRY shares were sold short, 19.1% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 11.1 trading days (days to cover). See the history.
Which famous investors hold SPRY?
5 of the 50 well-known investors we track reported SPRY in their latest 13F filing, including Israel Englander, Ken Griffin, Dan Loeb. The largest position is worth $14.1M. See all holders.
Executive pay
ARS Pharmaceuticals's chief executive was paid a total of $9.7M for the year ended Dec 31, 2025, up 35% from $7.2M the year before. In the last 12 months, ARS Pharmaceuticals's executives and directors bought no stock on the open market and sold $284K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.